Torrent Pharmaceuticals Limited has successfully completed a United States Food and Drug Administration (USFDA) inspection of its Bileshwarpura oncology facility with zero observations. The pharmaceutical company announced this significant regulatory milestone in a communication to stock exchanges on April 10, 2026.

USFDA Inspection Details

The inspection covered the company's Bileshwarpura facility, which specializes in oncology drug manufacturing. The regulatory review was conducted over a four-day period and concluded without any findings or observations from the USFDA inspectors.

Regulatory Compliance Achievement

The zero observation outcome represents a clean inspection result, indicating that the facility met all USFDA manufacturing standards and regulatory requirements. This achievement is particularly significant for an oncology facility, where stringent quality controls and manufacturing practices are essential for producing cancer treatment medications.

Corporate Disclosure

Torrent Pharmaceuticals fulfilled its disclosure obligations by informing both major Indian stock exchanges about the inspection outcome. The company submitted the notification under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with investors and stakeholders.

The communication was signed by Chintan M. Trivedi, Company Secretary, and formally addressed to the listing departments of both BSE Limited and National Stock Exchange of India Limited. This regulatory filing demonstrates the company's commitment to maintaining proper corporate governance and timely disclosure practices.

Manufacturing Excellence

The successful completion of the USFDA inspection with zero observations reflects the company's robust quality management systems and manufacturing capabilities at its oncology facility. Such outcomes are crucial for pharmaceutical companies seeking to maintain their market access and regulatory standing in the United States, one of the world's largest pharmaceutical markets.

Torrent Power Limited has announced the sale of its equity stake in UNM Foundation to its holding company, marking a strategic restructuring within the corporate group. The power company disclosed this transaction to stock exchanges on March 30, 2026, in compliance with regulatory requirements under Regulation 30 of SEBI LODR.

Transaction Details

The sale involved 50,000 equity shares of UNM Foundation, each carrying a face value of ₹10.00. The total consideration for the transaction amounted to ₹5,00,000, with the shares being transferred to Torrent Investments Limited, which serves as the holding company and promoter of Torrent Power Limited.

Regulatory Compliance

The company has classified this as a related party transaction conducted at arm's length, as required under SEBI regulations. Since the shares were sold to the holding company, no formal sale agreement was entered into for this internal group restructuring. The disclosure was made pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

About UNM Foundation

UNM Foundation operates as a Section 8 company, which indicates its non-profit status under Indian corporate law. The company disclosed that UNM Foundation does not generate revenue or turnover, consistent with its Section 8 classification. This transaction represents a complete divestiture of Torrent Power's stake in the foundation.

Corporate Structure Impact

The sale consolidates UNM Foundation's ownership within the promoter group structure, with Torrent Investments Limited now holding the equity stake previously maintained by the power company subsidiary. This internal reorganization does not involve external parties and maintains the foundation within the broader Torrent corporate ecosystem.